Dr. Oh Discusses the Role of Chemotherapy in Prostate Cancer

Video

In Partnership With:

William K. Oh, MD, professor, Mount Sinai Hospital, discusses the current role of chemotherapy in the treatment of patients with prostate cancer.

William K. Oh, MD, professor, Mount Sinai Hospital, discusses the current role of chemotherapy in the treatment of patients with prostate cancer.

As new agents emerge and immunotherapies develops, many patients and some oncologists are quick to dismiss chemotherapy as a treatment option, Oh explains.

Chemotherapy has had a second life, says Oh, with the success of the STAMPEDE and CHAARTED trials in metastatic hormone-sensitive prostate cancer.

Also, there is a subset of patients, Oh suggests, who did not respond to primary androgen receptor (AR)-therapy who would be good candidates for chemotherapy, instead of a second AR-targeted therapy.

Related Videos
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH